EUVIMEDEUVIMED entdecken
Open Access

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Fergus Keane iD, Joanne F Chou, Henry Walch iD, Joshua Schoenfeld, Anupriya Singhal, Darren Cowzer, Emily Harrold, Catherine A O'Connor, Wungki Park iD, Anna Varghese, Imane El Dika, Fiyinfolu Balogun und 5 weitere

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Fergus Keane und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Precision Medicine, Mutation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, Paul Calabresi Career Development Award for Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed in 1%-2%. Several inhibitors of KRAS G12C have recently demonstrated promise in solid tumors, including pancreatic cancer. Little is known regarding clinical, genomics, and outcome data of this population.

Methods

Patients with pancreatic cancer and KRAS G12Cmut were identified at Memorial Sloan Kettering Cancer Center and via the American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database. Clinical, treatment, genomic, and outcomes data were analyzed. A cohort of patients at Memorial Sloan Kettering Cancer Center with non-G12C KRAS pancreatic cancer was included for comparison.

Results

Among 3571 patients with pancreatic ductal adenocarcinoma, 39 (1.1%) with KRAS G12Cmut were identified. Median age was 67 years, and 56% were female. Median body mass index was 29.2 kg/m2, and 67% had a smoking history. Median overall survival was 13 months (95% CI: 9.4 months, not reached) for stage IV and 26 months (95% CI: 23 months, not reached) for stage I-III. Complete genomic data (via American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database) was available for 74 patients. Most common co-alterations included TP53 (73%), CDKN2A (33%), SMAD4 (28%), and ARID1A (21%). Compared with a large cohort (n = 2931) of non-G12C KRAS-mutated pancreatic ductal adenocarcinoma, ARID1A co-mutations were more frequent in KRAS G12Cmut (P < .05). Overall survival did not differ between KRAS G12Cmut and non-G12C KRAS pancreatic ductal adenocarcinoma. Germline pathogenic variants were identified in 17% of patients; 2 patients received KRAS G12C-directed therapy.

Conclusion

Pancreatic cancer and KRAS G12Cmut may be associated with a distinct clinical phenotype. Genomic features are similar to non-G12C KRAS-mutated pancreatic cancer, although enrichment of ARID1A co-mutations was observed. Targeting of KRAS G12C in pancreatic cancer provides a precedent for broader KRAS targeting in pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Precision MedicineMutationCarcinoma, Pancreatic DuctalTranscription FactorsHumansFemaleMaleAgedMiddle AgedDNA-Binding ProteinsSmad4 ProteinNuclear ProteinsAged, 80 and overCyclin-Dependent Kinase Inhibitor p16Tumor Suppressor Protein p53GenomicsAdultBiomarkers, Tumor

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanTranscription FactorsSMAD4 protein, humanDNA-Binding ProteinsSmad4 ProteinARID1A protein, humanNuclear ProteinsCyclin-Dependent Kinase Inhibitor p16Tumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Fergus Keane, Henry Walch, Wungki Park, Rona Yaeger, Eileen M O'Reilly

Förderung

  • NIH HHS
  • NCI NIH HHS
  • Paul Calabresi Career Development Award for Clinical Oncology
  • Society of Immunotherapy for Cancer
  • NCI
  • MSK Parker Institute for Cancer Immunotherapy
  • Breakthrough Cancer-Conquering KRAS for Pancreatic Cancer
  • Cancer Center Support Grant/Core

Zitieren

APA

Keane, F., Chou, J. F., Walch, H., Schoenfeld, J., Singhal, A., Cowzer, D., Harrold, E., O'Connor, C. A., Park, W., Varghese, A., El Dika, I., Balogun, F., Yu, K. H., Capanu, M., Schultz, N., Yaeger, R., & O'Reilly, E. M. (2024). Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae095

Vancouver

Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, et al. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae095

BibTeX
@article{Keane2024,
  author = {Keane, Fergus and Chou, Joanne F and Walch, Henry and Schoenfeld, Joshua and Singhal, Anupriya and Cowzer, Darren and Harrold, Emily and O'Connor, Catherine A and Park, Wungki and Varghese, Anna and El Dika, Imane and Balogun, Fiyinfolu and Yu, Kenneth H and Capanu, Marinela and Schultz, Nikolaus and Yaeger, Rona and O'Reilly, Eileen M},
  title = {Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae095}
}
Kostenlos starten →